Shares surged 12.8% to $4.66 after Aquestive Therapeutics delivered first-quarter results that caught Wall Street off guard — and not just on revenue. The small New Jersey drugmaker is burning less cash, pulling in higher royalties, and pushing closer to FDA approval of a needle-free epinephrine product that could reshape how millions of allergy sufferers respond to emergencies. The question now: is the existing business strong enough to carry investors through the regulatory wait?
Royalty Revenue Exploded, Turning a Niche Manufacturer Into Something Bigger. Q1 revenue hit $14.4 million, up 66% year over year, while the net loss shrank to $8.1 million from $22.9 million.
The figure surpassed analyst expectations by 33%.
The surge was driven by manufacturing activity and $4.5 million in royalty revenue from a licensing partner, Zevra — up from less than $1 million a year ago. That shift matters because royalties are nearly pure profit; they don't require Aquestive to spend on raw materials or factory labor.
The Losses Are Shrinking, but the Company Still Burns Cash. Earnings per share improved to -$0.07 from -$0.24 a year ago.
Adjusted EBITDA loss — a measure of operating cash drain — was just $1.7 million.
Full-year guidance calls for $46–$50 million in revenue and an EBITDA loss of $30–$35 million , meaning Q1 was well ahead of a straight-line pace. That gap suggests royalties may be lumpy, so investors shouldn't assume every quarter looks this good.
The FDA Rejection Wasn't Fatal — and a $150 Million War Chest Backs the Resubmission. The FDA's January rejection letter flagged only packaging and usability issues, not safety or manufacturing problems.
Management confirmed it completed its FDA meeting and is targeting a Q3 2026 resubmission of its application for a postage-stamp-sized dissolving film that delivers epinephrine without needles. The company just refinanced into a $150 million debt facility with Oaktree Capital , and expects $150 million in cash available for a potential 2027 launch.
The Stock Is Still Down Sharply From Its Highs. AQST has a 52-week range of $2.12 to $7.55 , meaning today's pop still leaves shares nearly 40% below their peak. At least one analyst carries an $8 fair-value target , but that depends entirely on FDA approval — a binary event that could just as easily send shares lower if any new complications emerge.